Joel M Gelfand Highlights Platelet RNA Signature in Psoriasis
Joel M Gelfand, Director Center for Clinical Sciences in Dermatology at University of Pennsylvania School of Medicine, shared a post on LinkedIn:
“An under investigated topic in psoriasis is its impact on platelets. Here, Michael Garshick demonstrates that even when psoriasis is well controlled with biologics platelets remain activated and have a newly discovered RNA signature that predicts future cardiovascular events.
Details here
Álvaro González Cantero has also recently demonstrated that patients with well controlled psoriasis have residual systemic inflammation
Details here
These findings provide more evidence that simply treating the skin may not be enough to lower CV risk and that more holistic multi-pronged approaches are needed. Note, I am a collaborator and author on both papers”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 23:59Ana Pedrero Gil: Is Coagulopathy with Fibrinolysis Present in All Obstetric Hemorrhages?
-
Oct 9, 2026, 23:57Exploring the Psychosocial Needs of People with Bleeding Disorders in Kyrgyzstan – EAHAD
-
Oct 9, 2026, 23:53Bernard Slater Jr.: Serving on the Advisory Council for the NBDF West Virginia Chapter
-
Oct 9, 2026, 23:53Aurelio Maggio: Thalassemia Reports Real-Time Impact Factor Rises to 1.760
-
Oct 9, 2026, 23:52Stronger Connections, Stronger Organizations – World Federation of Hemophilia
-
Oct 9, 2026, 23:46Samuel Misiani Mbunya: Advancing Sickle Cell Care Through Collaboration at the 21st ASCAT Conference
-
Oct 9, 2026, 23:42Hadeel Swed: My First First-Author Publication in Thrombosis Research
-
Oct 9, 2026, 23:38Micheal Avoseh: Exploring Nanoparticle-Based Therapies for Thrombosis and Vascular Inflammation
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation